Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumors

Kaitlynn Moser, Michelle Soto, Daniela Geba, Paul Allen, Klaus Lindpaintner
doi: https://doi.org/10.1101/2022.04.01.22269254

Article Information

doi 
https://doi.org/10.1101/2022.04.01.22269254
History 
  • April 5, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Kaitlynn Moser1,
  2. Michelle Soto2,
  3. Daniela Geba3,
  4. Paul Allen2 and
  5. Klaus Lindpaintner1,*
  1. 1InterVenn Biosciences, 2 Tower Place, South San Francisco, CA 94080
  2. 2Olson Research Group, 1040 Stony Hill Road, Suite 125, Yardley, PA 19067
  3. 3Ascenian Consulting and Market Research, 1798 Trellis Circle, Webster, NY 14580
  1. ↵*Corresponding author:
    Klaus Lindpaintner, MD, MPH, Mailing address: InterVenn Biosciences, 2 Tower Place, South San Francisco, CA 94080, Email address: klaus{at}venn.bio
Back to top
Posted April 05, 2022.
Download PDF
Data/Code
Email
Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumors
Kaitlynn Moser, Michelle Soto, Daniela Geba, Paul Allen, Klaus Lindpaintner
medRxiv 2022.04.01.22269254; doi: https://doi.org/10.1101/2022.04.01.22269254
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area